image
Healthcare - Medical - Healthcare Information Services - NYSE - US
$ 9.4
-5.91 %
$ 1.1 B
Market Cap
-11.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one EVH stock under the worst case scenario is HIDDEN Compared to the current market price of 9.4 USD, Evolent Health, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one EVH stock under the base case scenario is HIDDEN Compared to the current market price of 9.4 USD, Evolent Health, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one EVH stock under the best case scenario is HIDDEN Compared to the current market price of 9.4 USD, Evolent Health, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EVH

image
$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.55 B REVENUE
30.09%
-40.5 M OPERATING INCOME
43.15%
-61.6 M NET INCOME
45.49%
18.8 M OPERATING CASH FLOW
-86.84%
-62.9 M INVESTING CASH FLOW
84.86%
-565 K FINANCING CASH FLOW
-0.20%
647 M REVENUE
4.05%
-18.6 M OPERATING INCOME
-14.31%
-22.8 M NET INCOME
1.45%
-26.2 M OPERATING CASH FLOW
-140.50%
-19.9 M INVESTING CASH FLOW
-1.02%
96.9 M FINANCING CASH FLOW
1176.18%
Balance Sheet Evolent Health, Inc.
image
Current Assets 607 M
Cash & Short-Term Investments 163 M
Receivables 428 M
Other Current Assets 15.6 M
Non-Current Assets 1.94 B
Long-Term Investments 8.59 M
PP&E 79.3 M
Other Non-Current Assets 1.85 B
6.43 %16.82 %3.12 %72.69 %Total Assets$2.5b
Current Liabilities 716 M
Accounts Payable 96 M
Short-Term Debt 198 M
Other Current Liabilities 421 M
Non-Current Liabilities 637 M
Long-Term Debt 25 M
Other Non-Current Liabilities 613 M
7.10 %14.65 %31.14 %45.27 %Total Liabilities$1.4b
EFFICIENCY
Earnings Waterfall Evolent Health, Inc.
image
Revenue 2.55 B
Cost Of Revenue 2.19 B
Gross Profit 367 M
Operating Expenses 408 M
Operating Income -40.5 M
Other Expenses 21.1 M
Net Income -61.6 M
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)3b(2b)367m(408m)(40m)(21m)(62m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
14.38% GROSS MARGIN
14.38%
-1.58% OPERATING MARGIN
-1.58%
-2.41% NET MARGIN
-2.41%
-6.15% ROE
-6.15%
-2.42% ROA
-2.42%
-1.95% ROIC
-1.95%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Evolent Health, Inc.
image
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -61.6 M
Depreciation & Amortization 118 M
Capital Expenditures -24.9 M
Stock-Based Compensation 39.7 M
Change in Working Capital -117 M
Others -111 M
Free Cash Flow -6.13 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Evolent Health, Inc.
image
Wall Street analysts predict an average 1-year price target for EVH of $26.4 , with forecasts ranging from a low of $14 to a high of $42 .
EVH Lowest Price Target Wall Street Target
14 USD 48.94%
EVH Average Price Target Wall Street Target
26.4 USD 181.32%
EVH Highest Price Target Wall Street Target
42 USD 346.81%
Price
Max Price Target
Min Price Target
Average Price Target
4545404035353030252520201515101055May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Evolent Health, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
9.63 M USD 5
9-12 MONTHS
0 USD 0
Bought
1.35 M USD 9
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript Evolent Health, Inc. (NYSE:EVH ) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Matthew Gillmor - KeyBanc Charles Rhyee - TD Cowen Andrea Alfonso - UBS Jailendra Singh - Truist Securities Ryan Daniels - William Blair Jeff Garro – Stephens Anne Samuel - J.P. Morgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler David Larsen - BTIG Daniel Grosslight – Citi Matthew Shea - Needham Operator Welcome to the Evolent Earnings Conference Call for the Fourth Quarter and Year End December 31, 2024. seekingalpha.com - 1 month ago
Evolent Health (EVH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Evolent Health (EVH) Reports Q4 Loss, Lags Revenue Estimates Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago. zacks.com - 1 month ago
Evolent Announces Fourth Quarter and Full Year 2024 Results Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively. Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively. prnewswire.com - 1 month ago
Evolent Health (EVH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. zacks.com - 2 months ago
Earnings Preview: Evolent Health (EVH) Q4 Earnings Expected to Decline Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Evolent Health Announces Changes to Board of Directors Richard " Rick "  Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb ' s Appointment as New Independent Director WASHINGTON , Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott. prnewswire.com - 2 months ago
New Strong Sell Stocks for January 30th DEC, ERO and EVH have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2024. zacks.com - 2 months ago
Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025 Company to Participate in Upcoming Conferences WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. prnewswire.com - 2 months ago
Evolent dips after Truist warns guidance may be 'significantly' below consensus Truist analyst Jailendra Singh caught up with Evolent Health post its presentation at an investor healthcare conference and also noted that the company released an 8-K earlier in the week outlining some preliminary views on 2025. Evolent is encouraging investors to use Q4 EBITDA run-rate as the baseline for 2025 and the firm now sees the company's 2025 guidance range coming in "significantly below consensus," the analyst tells investors. Using about $25M of Q4 EBITDA as a baseline, the firm infers that Evolent is suggesting a potential initial FY25 EBITDA range of $140M-$170M, said the analyst, who has a Buy rating and $20 price target on the shares. In Wednesday trading, Evolent shares slid 10% to $10.02. https://thefly.com - 3 months ago
Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1 Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON , Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. prnewswire.com - 4 months ago
New Strong Sell Stocks for December 12th ASH, BIDU and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 12, 2024. zacks.com - 4 months ago
8. Profile Summary

Evolent Health, Inc. EVH

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 1.1 B
Dividend Yield 0.37%
Description Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
Contact 800 North Glebe Road, Arlington, VA, 22203 https://www.evolenthealth.com
IPO Date June 5, 2015
Employees 4500
Officers Mr. Robert Cruz Chief Technology Officer Ms. Katie DiPerna Cook Chief People Officer Mr. Aammaad Shams Chief Accounting Officer Mr. Dan McCarthy President Mr. John Paul Johnson Chief Financial Officer Mr. Seth Barrie Blackley Co-Founder, Chief Executive Officer & Director Ms. Emily Rafferty Chief Operating Officer Mr. Jonathan David Weinberg J.D. Chief Legal Officer, General Counsel & Secretary Ms. Jessica White Chief Information Officer Mr. Seth R. Frank Vice President of Investor Relations